New hope for advanced cancer: first human trial of APR-1051 begins

NCT ID NCT06260514

First seen Jan 26, 2026 · Last updated May 08, 2026 · Updated 14 times

Summary

This early-stage study tests a new oral drug called APR-1051 in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose, while also looking for signs that it might shrink tumors. Participants will take the drug by mouth and be closely monitored for side effects and how their cancer responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MD Anderson Cancer Center (MDACC)

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

  • NEXT Oncology -Dallas

    RECRUITING

    Irving, Texas, 75039, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • NEXT Oncology -San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.